Fosamax and Osteonecrosis of the Jaw: Clinical Evidence Review

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health Information

The legacy context of general health and science information has long served as a foundation for public understanding of medical conditions and therapeutic interventions. Within this broad framework, discussions of bone health and pharmaceutical treatments have been standard topics, providing a baseline for both patients and providers. As this informational heritage evolved, it increasingly accommodated specialized inquiries into specific drug-safety profiles and adverse event reporting. One such area of focused attention involves the relationship between bisphosphonate therapy and oral health complications, particularly following long-term exposure. This pivot from general health education to a more targeted risk assessment reflects a natural progression in clinical awareness. The transition is marked by a shift from broad preventive health messaging to detailed consideration of exposure scenarios that may elevate concern. In the context of mass production environments, where pharmaceutical compounds are handled at scale, the relevance of such clinical evidence becomes particularly acute. Occupational exposure to bisphosphonates, whether through manufacturing processes or formulation activities, introduces a distinct dimension of risk that warrants careful evaluation. The bridge from general health information to this occupational exposure concern is built upon the recognition that clinical findings from patient populations can inform workplace safety protocols. Thus, the legacy of general health science now supports a more granular examination of exposure pathways in industrial settings.

Clinical Evidence Linking Fosamax to Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). While effective in reducing fracture risk, its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of exposed bone that persist for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is based on clinical examination and imaging, with a focus on ruling out metastatic disease or other causes of jaw necrosis. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Pharmacology and Risk Factors

The pharmacology of Fosamax involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover. This mechanism, while beneficial for increasing bone mass and reducing fractures, may also impair the jawbone's ability to remodel and repair microdamage, particularly after dental procedures. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are thought to involve suppression of bone turnover, leading to accumulation of microdamage and impaired healing. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw, and may inhibit angiogenesis, further compromising blood supply. The resulting avascular necrosis can be exacerbated by local infection or trauma.

Causation and Temporal Relationship

Causation-related considerations for affected patients include the need to establish a temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting that ONJ is a rare event that may require additional risk factors. The timeline between exposure and documented harm can range from months to years, with risk increasing with duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who develop ONJ should discontinue Fosamax and receive appropriate dental care, including debridement, antibiotics, and pain management. Rechallenge with the same drug or another bisphosphonate may lead to recurrence of symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Clinical Management

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4: "Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including FOSAMAX" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not specify a recommended duration of discontinuation before dental procedures, and the optimal duration of use for Fosamax has not been determined (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, Fosamax is associated with a risk of ONJ, particularly in patients with additional risk factors such as invasive dental procedures, cancer, or concomitant therapies. The prescribing information provides warnings about this risk, but the optimal management strategy for patients requiring dental procedures remains unclear. Clinicians should weigh the benefits of Fosamax in reducing fracture risk against the potential for ONJ, especially in patients with prolonged exposure or other risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and what is it used for?

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with tooth extraction or local infection. Fosamax use has been linked to ONJ, particularly with prolonged exposure and additional risk factors such as invasive dental procedures, cancer, or concomitant therapies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.